<DOC>
	<DOCNO>NCT02438202</DOCNO>
	<brief_summary>Electroconvulsive therapy ( ECT ) induce cerebral seizure electrical stimulation general anesthesia muscle relaxation , regard highly efficient ( specific severe psychiatric disorder ) extremely safe modern treatment option . Alzheimer´s disease ( AD ) neurodegenerative disorder characterize progressive cognitive deterioration accompany decline activity daily live , variety behavioral disturbance neuropsychiatric symptom . The clinical progression disease delay pharmaceutical therapy like acetylcholinesterase inhibition ( e.g . rivastigmine ) 6 12 month . Along well-known biomarkers AD ( Aß- tau-proteins ) low brain-derived neurotrophic factor ( BDNF ) level since recently consider negative predictor disease course . In animal experimental study possible arrest disease progression aid neurotrophic substance . Many single study , also number meta-analyses show primary gray matter atrophy hippocampal , parahippocampal medial temporal brain region . Strikingly , ECT yield exact opposite effect cause AD : ECT series lead increase serum BDNF-levels patient . Parallel observation evidence exist gray matter volume gain ECT series , especially hippocampus . There sufficient clinical experience regard use ECT AD-patients , mainly basis follow indication : ) affective disorder b ) behavioral disturbance . A positive effect ECT symptoms agitation aggression assess AD patient alongside good tolerability . To investigate potential salutary effect ECT AD investigator design pilot study follow concept : Patients confirm AD diagnosis preexist stable antidementia medication least 6 month receive modify maintenance ECT total 27 week . In propose pilot study , investigator hypothesize cognitive functioning AD patient improve significantly independently affective symptom , initial final examination compare . The affirmation hypothesis would provide insight mechanism action ECT also important reference point development new treatment option so-far incurable disease .</brief_summary>
	<brief_title>Electroconvulsive Therapy Treatment Alzheimer´s Disease</brief_title>
	<detailed_description>Electroconvulsive therapy ( ECT ) induce cerebral seizure electrical stimulation general anesthesia muscle relaxation , regard highly efficient ( specific severe psychiatric disorder ) extremely safe modern treatment option . Alzheimer´s disease ( AD ) neurodegenerative disorder characterize progressive cognitive deterioration accompany decline activity daily live , variety behavioral disturbance neuropsychiatric symptom . All currently available treatment remain palliative nature . The clinical progression disease delay pharmaceutical therapy like acetylcholinesterase inhibition ( e.g . rivastigmine ) 6 12 month . Along well-known biomarkers AD ( Aß- tau-proteins ) low brain-derived neurotrophic factor ( BDNF ) level since recently consider negative predictor disease course . In animal experimental study possible arrest disease progression aid neurotrophic substance . Many single study , also number meta-analyses show primary gray matter atrophy hippocampal , parahippocampal medial temporal brain region . Strikingly , ECT yield exact opposite effect cause AD : ECT series lead increase serum BDNF-levels patient . Parallel observation evidence exist gray matter volume gain ECT series , especially hippocampus . There sufficient clinical experience regard use ECT AD-patients , mainly basis follow indication : ) affective disorder b ) behavioral disturbance . A positive effect ECT symptoms agitation aggression assess AD patient alongside good tolerability . A recent review ECT treatment patient concomitant depression AD point patient significantly good score cognitive test 6 month ECT series . ECT psychiatric treatment cognitive enhancement AD uncharted scientific territory . To investigate potential salutary effect ECT AD investigator design pilot study follow concept : Patients confirm AD diagnosis preexist stable antidementia medication least 6 month receive modify maintenance ECT total 27 week . In propose pilot study , investigator hypothesize cognitive functioning AD patient improve significantly independently affective symptom , initial final examination compare . The affirmation hypothesis would provide insight mechanism action ECT also important reference point development new treatment option so-far incurable disease .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>confirm Diagnostic Statistical Manual Mental Disorders ( DSM IV ) diagnosis Alzheimer 's disease ( Mini Mental State Examination &gt; 5 &lt; 26 ) routine treatment AD due German national guideline ( `` S3Leitlinie '' ) Ability consent . If doubt independent ( study ) psychiatrist document ability consent . If ability consent state , legal guardian consent instead . No ECT perform patient 's . contraindication ECT current major depressive episode due DSM IV</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>